SillaJen Biotherapeutics To Present at the BIO Business Forum - CBS 3 Springfield - WSHM

SillaJen Biotherapeutics To Present at the BIO Business Forum

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE SillaJen, Inc.

BUSAN, South Korea and SAN FRANCISCO, June 20, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today that the company will make a presentation next week at the BIO Business Forum, which is a part of the 2014 BIO International Convention being held in San Diego, CA.  David McDonald, chief business officer of SillaJen, will present on Tuesday, June 24, 2014 at 2:15 pm. PT.

About SillaJen, Inc.
SillaJen, Inc., is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life-threatening cancers. The company's lead product candidate, Pexa-Vec (JX-594), is entering late-stage clinical development for the treatment of advanced primary liver cancer (Pexa-Vec described in Nature Reviews Cancer, Kirn et al 2009). High-dose Pexa-Vec treatment was associated with an overall survival benefit in a randomized Phase 2 trial in patients with 1st-line liver cancer (Nature Medicine, 2013). Pexa-Vec also demonstrated unique IV delivery to solid tumors, and objective tumor responses, as reported in Nature (2011). Pexa-Vec is in mid-stage development for kidney cancer and other solid tumors. The company is also developing a robust pipeline of oncolytic immunotherapy products with multiple complementary mechanisms-of-action. 

Born from a desire to revolutionize therapeutic approaches for patients with serious unmet medical needs, and honed through years of pioneering experience guiding oncolytic vaccinia through clinical trials in Korea, the U.S. and around the world, SillaJen is uniquely poised for rapid and efficient clinical development of cutting-edge gene and viral therapies. SillaJen acquired Jennerex Inc (San Francisco, California) in 2014. SillaJen is headquartered in Busan, South Korea with labs in Busan and offices in San Francisco, California.  Additional information about SillaJen can be found at www.sillajen.com.

Contact:
Jennifer Williams
Investor and Media Relations
Cook Williams Communications, Inc.
jennifer@cwcomm.org

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
WSHM
Powered by WorldNow CNN
All content © 2014, WSHM; Springfield, MA. (A Meredith Corporation Station) and WorldNow. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.